{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:38:22Z","timestamp":1790041102420,"version":"4.0.1"},"reference-count":52,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,22]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>N-methylated thrombospondin-1 mimetic peptides selectively kill the leukemic CD5+ B cells, sparing mature and precursor nontumor cells. CD47 peptide triggering eliminates drug-resistant CLL cells by inducing an original form of cell death regulated by G proteins.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000350","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T21:27:46Z","timestamp":1571261266000},"page":"2920-2933","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1\u2013derived peptides overcomes drug resistance"],"prefix":"10.1182","volume":"3","author":[{"given":"Elodie","family":"Pramil","sequence":"first","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Sorbonne Universit\u00e9, Ecole Normale Sup\u00e9rieure, Paris Sciences & Lettres University Paris, Centre National de la Recherche Scientifique, Laboratoire des Biomol\u00e9cules, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Herbi Bastian","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-7997","authenticated-orcid":false,"given":"Thomas","family":"Den\u00e8fle","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Ecole Normale Sup\u00e9rieure, Paris Sciences & Lettres University Paris, Centre National de la Recherche Scientifique, Laboratoire des Biomol\u00e9cules, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Nemati","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris Sciences & Lettres University Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malina","family":"Xiao","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lard\u00e9","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Ecole Normale Sup\u00e9rieure, Paris Sciences & Lettres University Paris, Centre National de la Recherche Scientifique, Laboratoire des Biomol\u00e9cules, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-4801","authenticated-orcid":false,"given":"Karim","family":"Maloum","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Biologique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-755X","authenticated-orcid":false,"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Clinique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-7596","authenticated-orcid":false,"given":"Elise","family":"Chapiro","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Biologique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3240","authenticated-orcid":false,"given":"Magali","family":"Le Garff-Tavernier","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Biologique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Davi","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Biologique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Decaudin","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris Sciences & Lettres University Paris, Paris, France;"},{"name":"Department of Medical Oncology, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2318-0713","authenticated-orcid":false,"given":"Marika","family":"Sarfati","sequence":"additional","affiliation":[{"name":"Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-6668","authenticated-orcid":false,"given":"Florence","family":"Nguyen-Khac","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Biologique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-1143","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Merle-B\u00e9ral","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service d\u2019H\u00e9matologie Biologique, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-6474","authenticated-orcid":false,"given":"Philippe","family":"Karoyan","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Ecole Normale Sup\u00e9rieure, Paris Sciences & Lettres University Paris, Centre National de la Recherche Scientifique, Laboratoire des Biomol\u00e9cules, Paris, France;"},{"name":"Kayvisa, AG, Zug, Switzerland; and"},{"name":"Kaybiotix, GmbH, Baar, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-1628","authenticated-orcid":false,"given":"Santos A.","family":"Susin","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Hematological Disorders Team, INSERM UMRS_1138, Sorbonne Universit\u00e9, Universit\u00e9 Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Universit\u00e9 Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"issue":"6","key":"2019111522211570800_B1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.semcancer.2010.09.003","article-title":"Molecular basis of CLL","volume":"20","author":"Pekarsky","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2019111522211570800_B2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MOH.0b013e32836235dc","article-title":"Genetic and epigenetic basis of chronic lymphocytic leukemia","volume":"20","author":"Mart\u00edn-Subero","year":"2013","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"2019111522211570800_B3","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia","volume":"122","author":"Gaidano","year":"2012","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111522211570800_B4","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2019111522211570800_B5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/leu.2017.100","article-title":"Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1","volume":"31","author":"Cosson","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2019111522211570800_B6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/gcc.22176","article-title":"14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"53","author":"Cosson","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"24","key":"2019111522211570800_B7","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111522211570800_B8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"25","key":"2019111522211570800_B9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019111522211570800_B10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111522211570800_B11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"2019111522211570800_B12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111522211570800_B13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"11","key":"2019111522211570800_B14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/15233","article-title":"CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia","volume":"5","author":"Mateo","year":"1999","journal-title":"Nat Med"},{"issue":"3","key":"2019111522211570800_B15","doi-asserted-by":"crossref","first-page":"e1001796","DOI":"10.1371\/journal.pmed.1001796","article-title":"CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLC\u03b31 activation: evidence from mice and humans","volume":"12","author":"Martinez-Torres","year":"2015","journal-title":"PLoS Med"},{"issue":"5473","key":"2019111522211570800_B16","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"issue":"6","key":"2019111522211570800_B17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"issue":"2","key":"2019111522211570800_B18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2019111522211570800_B19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/14728222.2013.733699","article-title":"Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47","volume":"17","author":"Soto-Pantoja","year":"2013","journal-title":"Expert Opin Ther Targets"},{"issue":"17","key":"2019111522211570800_B20","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111522211570800_B21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"8","key":"2019111522211570800_B22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"2019111522211570800_B23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111522211570800_B24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2019111522211570800_B25","doi-asserted-by":"crossref","first-page":"e41972","DOI":"10.1371\/journal.pone.0041972","article-title":"CD47(low) status on CD4 effectors is necessary for the contraction\/resolution of the immune response in humans and mice","volume":"7","author":"Van","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"2019111522211570800_B26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2009.07.021","article-title":"Selective control of SIRP-alpha-positive airway dendritic cell trafficking through CD47 is critical for the development of T(H)2-mediated allergic inflammation","volume":"124","author":"Raymond","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"18","key":"2019111522211570800_B27","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.1021\/acs.jmedchem.6b00781","article-title":"Thrombospondin-1 mimetic agonist peptides induce selective death in tumor cells: design, synthesis, and structure-activity relationship studies","volume":"59","author":"Den\u00e8fle","year":"2016","journal-title":"J Med Chem"},{"issue":"10","key":"2019111522211570800_B28","doi-asserted-by":"crossref","first-page":"e76607","DOI":"10.1371\/journal.pone.0076607","article-title":"Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease","volume":"8","author":"Hertlein","year":"2013","journal-title":"PLoS One"},{"issue":"26","key":"2019111522211570800_B29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111522211570800_B30","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/cam4.2123","article-title":"Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia","volume":"8","author":"Kostopoulou","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"2019111522211570800_B31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"Dietrich","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111522211570800_B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gde.2007.12.006","article-title":"Microenvironmental regulation of cancer development","volume":"18","author":"Hu","year":"2008","journal-title":"Curr Opin Genet Dev"},{"issue":"9","key":"2019111522211570800_B33","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/emboj.2010.43","article-title":"AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX","volume":"29","author":"Artus","year":"2010","journal-title":"EMBO J"},{"issue":"13","key":"2019111522211570800_B34","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/MCB.02141-06","article-title":"Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis","volume":"27","author":"Moubarak","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2019111522211570800_B35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.drup.2004.11.003","article-title":"Cancer cell death by programmed necrosis?","volume":"7","author":"Borst","year":"2004","journal-title":"Drug Resist Updat"},{"issue":"23","key":"2019111522211570800_B36","first-page":"6167","article-title":"The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin","volume":"54","author":"Furuya","year":"1994","journal-title":"Cancer Res"},{"issue":"19","key":"2019111522211570800_B37","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/s00018-017-2547-4","article-title":"Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure","volume":"74","author":"M\u00fcller","year":"2017","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2019111522211570800_B38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbrc.2018.07.100","article-title":"The ferroptosis inducer erastin promotes proliferation and differentiation in human peripheral blood mononuclear cells","volume":"503","author":"Wang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2019111522211570800_B39","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/leu.2011.357","article-title":"Dysregulation of TNF\u03b1-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2019111522211570800_B40","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.4049\/jimmunol.170.7.3544","article-title":"The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A","volume":"170","author":"Manna","year":"2003","journal-title":"J Immunol"},{"issue":"3","key":"2019111522211570800_B41","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-03-1708","article-title":"CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A","volume":"64","author":"Manna","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"2019111522211570800_B42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/jpet.104.078311","article-title":"Suramin disrupts receptor-G protein coupling by blocking association of G protein alpha and betagamma subunits","volume":"313","author":"Chung","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl 1","key":"2019111522211570800_B43","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1038\/sj.bjp.0706405","article-title":"Heterotrimeric G-proteins: a short history","volume":"147","author":"Milligan","year":"2006","journal-title":"Br J Pharmacol"},{"key":"2019111522211570800_B44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-39406-0_6","article-title":"Immunogenic apoptotic cell death and anticancer immunity","volume":"930","author":"Vandenabeele","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"2019111522211570800_B45","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"46","key":"2019111522211570800_B46","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"2019111522211570800_B47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1074\/jbc.271.1.21","article-title":"Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin","volume":"271","author":"Gao","year":"1996","journal-title":"J Biol Chem"},{"issue":"12","key":"2019111522211570800_B48","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1016\/S0021-9258(18)52946-X","article-title":"Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin","volume":"268","author":"Kosfeld","year":"1993","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111522211570800_B49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"issue":"5","key":"2019111522211570800_B50","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/leu.2008.321","article-title":"Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia","volume":"23","author":"Merle-B\u00e9ral","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2019111522211570800_B51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/cas.13885","article-title":"CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells","volume":"110","author":"Uscanga-Palomeque","year":"2019","journal-title":"Cancer Sci"},{"issue":"26","key":"2019111522211570800_B52","doi-asserted-by":"crossref","first-page":"23915","DOI":"10.1074\/jbc.M301869200","article-title":"CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis","volume":"278","author":"Lamy","year":"2003","journal-title":"J Biol Chem"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/2920\/1248620\/advancesadv2019000350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/2920\/1248620\/advancesadv2019000350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T01:18:41Z","timestamp":1611537521000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/20\/2920\/375125\/Targeting-chronic-lymphocytic-leukemia-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":52,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000350","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]}}}